



Europass Curriculum Vitae

Personal information

First name(s) / Surname(s) **Antonio Giacomo Maria Addis**
Address Via Alessandro Volta, 42, 00153 Rome (Italy)
Telephone(s) +39 06 45582922 (home); 051 527.7450 - 7451 (office) Mobile +39 335 1421006
Fax(es) +39 051 527.7053
E-mail(s) aaddis@regione.emilia-romagna.it; agmaddis@gmail.com
Nationality Italian
Date of birth 01/01/1964
Gender Male

Work experience

Dates 01/01/2012 →
Occupation or position held Coordinator
Main activities and responsibilities Research Governance at Agenzia Sanitaria e Sociale Regionale dell'Emilia Romagna
Name and address of employer Agenzia sanitaria e sociale regionale
Via Aldo Moro 21, 40127 Bologna (Italy)
Type of business or sector Research governance in Public Health

Dates 15/11/2009 - 31/12/2011
Occupation or position held National Expert on secondment
Main activities and responsibilities

- To provide peer reviews of risk management plans for centrally authorised products, particularly on pandemic vaccines and antiviral medicines.
- To conduct signal detection for allocated centrally authorised products and liaise with Rapporteurs for the assessment of the signals.
- Provide expert advice in all areas of pharmacovigilance to support Product Team Leaders, Rapporteurs and scientific committees.
- To prepare standard operating procedures and contribute to the preparation of guidelines, position statements, etc..
- Representative in the Pandemic task force, and other expert groups in relation to pharmacovigilance and risk management of pandemic vaccines and antivirals

Name and address of employer European Medicine Agency
7 Wstferry Circus, E14 4HB London (United Kingdom)
Type of business or sector Pharmacovigilance Unit - Risk Management Setion

Dates 01/05/2008 - 01/11/2009
Occupation or position held Alternate Member of the Committee for Medicinal Products for Human Use (CHMP)- European Medicine Agency
Main activities and responsibilities

- Rapporteur and assessor for pre-pandemic and pandemic vaccines.
- Rapporteur for several centralized medicinal products
- Clinical Assessor for drugs with specific reference to drug use for mother and child health including vaccine.
- Participant to several Scientific committees at national and international level such as the European Task Force for pandemic vaccines or Gruppo di Lavoro sui Vaccini Interministeriale

Name and address of employer Agenzia Italiana del Farmaco

	via Sierra Nevada 62, 00100 Roma (Roma)
Dates	01/05/2008 - 01/10/2008
Occupation or position held	Head of European Drug Assessment Unit (interim)
Main activities and responsibilities	Coordinating the activities for the assessments of drugs authorization (Italy rapporteur) for the Committee for Medicinal Products for Human Use (CHMP)
Name and address of employer	Agenzia Italiana del Farmaco via Sierra Nevada 62, 00100 Roma (Italy)
Type of business or sector	
Dates	01/05/2005 - 14/11/2009
Occupation or position held	Director of the Drug Information Unit – Information, Clinical Trials and Research Department
Main activities and responsibilities	Editor of the National Drug Therapeutic Bulletin Coordinator for several educational activities facilitating the transfer of reliable clinical and therapeutic evidence to health operators (e.g., Editor for the Italian edition of the British National Formulary and CLinical Evidence); Coordinator for the AIFA continuous medical education programme based on Clinical Evidence and other sources Evidence Based Representing the National Medicine Agency (AIFA) in the National System of Guidelines
Name and address of employer	Health Technology assessment projects Agenzia Italiana del Farmaco via Sierra Nevada, 00100 Roma (Italy)
Type of business or sector	Information, Clinical Trials and Research Department
Dates	01/07/2002 - 31/05/2005
Occupation or position held	Head of Drug Information Unit
Main activities and responsibilities	Responsible for the editorial activities of the Directorate General of Medicines and Medical Devices (Ministry of Health) Coordination of several drug utilization studies with the aims to collect pharmacoepidemiological data useful for regulatory decisions. National regulatory activities concerning risk communication and pharmacovigilance including vaccines. Health Tecnology assessment projects
Name and address of employer	I have been coordinator for the publication of the National Pharmaceutical Formulary Ministry of Health via della Civiltà Romana, 00100 Roma (Italy)
Type of business or sector	Ministry of Health – Directorate General of Medicines and Medical Devices, Roma, Italy
Dates	01/07/2000 - 30/06/2002
Occupation or position held	Full time Resercher
Main activities and responsibilities	Health Technology Assessment programme regarding drug therapies Clinical assessor in the Panel of National Guideline System (SNLG) Italian evidence-based guidelines for the management of influenza-like syndrome in adults and children
Name and address of employer	Responsible and principal investigator for Drug utilization studies and Pharmacoepidemiology Center for the evaluation of effectiveness of health care (CeVEAS) Centro per la Valutazione dell'Efficacia e dell'Assistenza Sanitaria, Modena, Italy viale Muratori 201, Modena (Italy)
Type of business or sector	Health Techology Assessment
Dates	02/09/1997 - 30/06/2002
Occupation or position held	Full time Researcher
Main activities and responsibilities	Principal investigator for studies regarding the definition of safety of drugs use in pregnancy and

	during the first years of life. Design and coordination for several pharmacoepidemiological studies on drug use in pregnancy and in children including vaccines. Principal investigator for meta-analysis of drug safety data with observational studies.
Name and address of employer	"Mario Negri" Institute for Pharmacological Research, Milano, Italy Via Eritrea 62, Milano (Italy)
Type of business or sector	Laboratory for Mother and Child Health
Dates	02/02/1995 - 01/09/1997
Occupation or position held	Post-doctoral Fellow
Main activities and responsibilities	Studies regarding the definition of safety of drugs use in pregnancy and during the first years of life. Design and coordination of pharmacoepidemiological studies on drug use in pregnancy and in children. Researcher for the Motherisk programme performing pharmacoepidemiology studies (cohort, case control, meta-analysis studies) on drug use in pregnancy and children.
Name and address of employer	The Hospital for Sick Children, Toronto, Canada 555 UNIVERSITY AVE, M5G 1X8 Toronto (Canada)
Type of business or sector	Division of CLinical Pharmacology
Dates	01/02/1995 - 01/09/1997
Occupation or position held	Visiting Scientist
Main activities and responsibilities	Assistant professor in the sector of Pharmacoepidemiology. Principal investigator for meta-analysis of drug safety data with observational studies Principal investigator of pharmacoepidemiological and pharmacoconomics studies. Pharmacovigilance studies regarding the benefit risk profile of drug use for mother and child health.
Name and address of employer	University of Toronto, Faculty of Pharmacy, Toronto, Canada 144 College Street, M5S 3M2 Toronto (Canada)
Type of business or sector	Pharmacoepidemiology
Dates	01/01/1994 - 02/02/1995
Occupation or position held	Post doctoral Fellow
Main activities and responsibilities	Studies regarding the definition of safety of drugs use in pregnancy and during the first years of life. Designed and coordination as principal investigator of pharmacoepidemiological studies (prospective and retrospective cohort studies) on drug use in pregnancy and in children including vaccines
Name and address of employer	"Mario Negri" Institute for Pharmacological Research, Milano, Italy via Eritrea 62, Milano (Italy)
Type of business or sector	Laboratory for Mother and Child Health

Education and training

Dates	01/08/1991 - 31/12/1993
Title of qualification awarded	PhD Fellow on Pharmacological Research
Principal subjects / occupational skills covered	PhD Fellow at the Regional School for Pharmacological research. Studies on drug safety in pregnancy and in children. Drug Utilization in pregnancy and analysis of safety of new vaccines such as MMR and Pertussis in children. Researcher on pharmacoepidemiological studies on use of drug in children and in pregnant women
Name and type of organisation providing education and training	School of Region Lombardia, "Mario Negri" Institute for Pharmacological Research, Milano, Italy (PhD) via Eritrea 62, Milano (Italy)
Level in national or international classification	Post Graduate - Specialization in Pharmacological Research Ph D Equivalent

Dates 01/09/1988 - 31/07/1991
 Title of qualification awarded Fellow as civil servant
 Principal subjects / occupational skills covered Trainee in the the Laboratory of cholinergic system doing basic non clinical research on animal model for CNS Drugs
 Name and type of organisation providing education and training "Mario Negri" Institute for Pharmacological Research, Milano, Italy via Eritrea 62, Milano (Italy)
 Level in national or international classification Trainee

Dates 01/09/1983 - 01/07/1991
 Title of qualification awarded Graduation on Chemical Pharmacy
 Principal subjects / occupational skills covered Chemical and Technological Pharmacy Milano, Italy
 The course of Chemical Pharmacy in Italy is of 5 years with compulsory discussion of experimental thesis before the final graduations.
 I spent the last two years of my university course working in the Laboratory of cholinergic system of the Mario Negri Insitute studying on animal models the activity of several CNS drugs
 Name and type of organisation providing education and training Faculty of Chemical Pharmacy - Universita' Statale di Milano, Milan, Italy (5 years of University) via Bartolini, Milano (Italy)
 Level in national or international classification Dottore in Chimica e Tecnologia Farmaceutica

Dates 01/09/1978 - 30/06/1983
 Title of qualification awarded High level school degree
 Name and type of organisation providing education and training Liceo Classico Bernardo Demuro 00729 Tempio Pausania, Sassari (Italy)
 Level in national or international classification Diploma di Maturita' Classica

Personal skills and competences

Other language(s)

Self-assessment
 European level (*)

English
Spanish / Castilian
French

Understanding				Speaking				Writing	
Listening		Reading		Spoken interaction		Spoken production			
C2	Proficient user	C2	Proficient user	C2	Proficient user	C2	Proficient user	C2	Proficient user
A2	Basic User	A2	Basic User	A2	Basic User	A2	Basic User	A2	Basic User
A2	Basic User	A1	Basic User	A2	Basic User	A2	Basic User	A1	Basic User

(*) *Common European Framework of Reference (CEF) level*

Social skills and competences

I dedicate most of my time extra work to follow my two children enjoying the family duties.

Organisational skills and competences

I had several appointments at international level, mostly representing the Italian Medicine Agency and/or the Ministry of Health (e.g., Pharmaceutical Forum – Working Group on Relative Effectiveness 2007-2008; Pharmaceutical Forum – Public Private Partnership on Information to Patients; HMA WGCP HMA WG Communication Professionals- EMEA 2007-2008

Technical skills and competences

Thorough knowledge and experience of European Pharmaceutical Legislation and Industry gained in one EU country and at EMEA level.

Expertise in European/International Regulatory Affairs and Prescribing Information issues in particular.

Experienced on Pharmacoepidemiology and Drug Information research in term of design, conduct and assess ad hoc studies

	Experienced on Drug use in mother and child health including vaccine
	Experience on Drug Information techniques, medical writing and editorial activities
	Rapporteur and assessor for pre-pandemic and pandemic vaccines
	Clinical Assessor for drugs with specific reference to drug use for mother and child health including vaccine.
	Experienced in Drug Utilization and Pharmacoeconomical analysis.
	Experience on bibliographic search and on scientific literature databases
Computer skills and competences	Eudravigilance certificated user.
	Experience on data analysis and special expertise with programme to retrieve from bibliographic databases with the aim to perform meta-analysis.
	I am user friendly of MS Word for Windows (Advanced), MS Outlook, MS Excel, MS PowerPoint, Reference manager and EPI INFO.
	Experience on data retrieval from literature databases
Artistic skills and competences	I am an avid reader. I regularly swim and I loved sailing. I also play chess. Cinema has always been my passion. I enjoyed writing for some web base magazines commentaries on new movies releases.
Driving licence(s)	B
Additional information	Selection of Publications in peer reviewed journals and Scientific Books Palmieri L, Rielli R, Demattè L, Donfrancesco C, La Terza G, De Sanctis Caiola P, Dima F, Lo Noce C, Giannelli AM, Brignoli O, Cuffari A, De Rosa M, Addis A, Laurendi G, Giampaoli S. Cardiovascular Risk Observatory: preliminary results G Ital Cardiol. 2010;11:154-61. Tedeschi G, Amato MP, D'Alessandro R, Drago F, Milanese C, Popoli P, Rossi P, Savettieri G, Tola MR, Vanacore N, Covezzoli A, De Rosa M, Comi G, Pozzilli C, Bertolotto A, Marrosu MG, Grimaldi LM, Piccinni C, Montanaro N, Periotto L, Iommelli R, Addis A, Martini N, Provinciali L, Mancardi GL. The pharmacovigilance program on natalizumab in Italy: 2 years of experience. Neurol Sci. 2009 Suppl 2:S163-5. Joppi R, Demattè L, Menti AM, Pase D, Poggiani C, Mezzalira L; Italian Horizon Scanning Project Group. The Italian Horizon Scanning Project. Eur J Clin Pharmacol. 2009; 65:775-81 Naldi L, Addis A, Chimenti S, Giannetti A, Picardo M, Tomino C, Maccarone M, Chatenoud L, Bertuccio P, Caggese E, Cuscito R. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the psocare project. Dermatology. 2008; 217:365-373 Mancardi GL, Amato MP, D'Alessandro R, Drago F, Milanese C, Popoli P, Provinciali L, Rossi P, Savettieri G, Tedeschi G, Tola MR, Vanacore N, Covezzoli A, De Rosa M, Piccinni C, Montanaro N, Periotto L, Addis A, Martini N. Natalizumab: a country-based surveillance program. Neurol Sci. 2008 Sep;29 Suppl 2:S235-7

Addis A, Deambrosio P, Martini N The Italian criteria for the reimbursement of innovative advanced therapies. *Challenges in New Advanced Therapies*, Eds. G. Nisticò, M. Papaluca Amati & D. Brasseur.(EXORMA) 2008 Pag. 105-114.

Moja L, Moschetti I, Cinquini M, Sala V, Compagnoni A, Duca P, Deligant C, Manfrini R, Clivio L, Satolli R, Addis A, Grimshaw JM, Dri P, Liberati A. Clinical Evidence Continuous Medical Education: a randomised educational trial of an open access e-learning program for transferring evidence-based information - ICEKUBE (Italian Clinical Evidence Knowledge Utilization Behaviour Evaluation) - Study protocol Implementation. *Science Biome Central* 2008, 3:37

Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D. Response to the letter by Williams et al. *Intensive Care Med.* 2007; 33(8):1490-1.

Moja L, Moschetti I, Liberati A, Manfrini R, Deligant C, Satolli R, Addis A, Martini N, Dri P. Using Clinical Evidence in a national continuing medical education program in Italy. *PLoS Med.* 2007; 4(5): 113.

Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D. Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. *Intensive Care Med.* 2007; 33(3): 426-34.

Mastroiacovo P, Addis A Folic acid: a public-health challenge. *Lancet* 2006;367 (9528):2057.

Giampaoli S, Palmieri L, Donfrancesco C, Panico S, Pilotto L, Addis A, Boccanelli A, Di Pasquale G, Brignoli O, Filippi A, Vanuzzo D. Assessment of the absolute global cardiovascular risk: comparison between the risk chart and the individual score of the CUORE Project. *Giornale italiano di cardiologia.* 2006 May;7:359-64.

Addis A, Martini N. EBM e politica del farmaco. In: Liberati A, ed. *Etica, conoscenza e sanità.* Il Pensiero Scientifico Editore 2005; 337-351.

Addis A, co-autore. *Uso e applicazione della carta del rischio cardiovascolare.* Il Pensiero Scientifico Editore 2005.

Giampaoli S, Vanuzzo D, Palmieri L, Panico S, Lo Noce C, Dima F, Donfrancesco C, Troiani M, Greco D, D'Argenio P, Laurendi G, Addis A. Prevenzione, fattori di rischio e stili di vita. *Rischio cardiovascolare globale assoluto. Rapporto Osservasalute 2005. Stato di salute e qualità dell'assistenza nelle regioni italiane.* Prex S.p.a. Editore: 271-272.

Giampaoli S, Palmieri L, Donfrancesco C, Panico S, Pilotto L, Addis A, Boccanelli A, Di Pasquale G, Brignoli O, Filippi A, Ventriglia G, Vanuzzo D a nome del Gruppo di ricerca dell'Osservatorio Epidemiologico cardiovascolare. Progetto Cuore I.S.S.: carta e punteggio. *Società Italiana di Medicina Generale* 2005, 5/6: 17-22.

Addis A. (co-ed) *The motherisk Guide to Cancer in Pregnancy and Lactation.* Koren G, Lishner M, Santiago S eds. The Hospital for Sick Children. 2005.

Addis A. Prevenzione delle malattie cardiovascolari: il ruolo dell'organo regolatore. *Ital Heart J.* 2004;5 Suppl 8:73S-77S; discussion 84S-85S, 116S-121S.

Filibeck U, Addis A, Tomino C, Martini N. European Clinical Trials Directive: the Italian position. *Lancet.* 2004;363:1651-2.

Rocchi F, Addis A, Martini N. Current national initiatives about drug policies and cost control in Europe: the Italy example. *Journal of Ambulatory Care Management*. 2004;27:127-31.

Folino-Gallo P, Addis A, Bruzzone M, Conforti A, Moretti U, Leone R, Tosolini F, Velo G. L'assistenza farmaceutica territoriale. Rapporto Osservasalute 2003. Stato di salute e qualità dell'assistenza nelle regioni italiane. Vita e pensiero Editore: 275-89.

Formoso G, Moja L, Nonino F, Dri P, Addis A, Martini N, Liberati A. Clinical Evidence: a useful tool for promoting evidence-based practice? *BMC Health Serv Res*. 2003 Dec 23;3:24.

Traversa G, Magrini N, Addis A e Gruppo di lavoro OsMed. Il consumo e la spesa farmaceutica: una valutazione comparata tra regioni. I servizi sanitari in Italia. Il Mulino. 2003.

EURO-MED-STAT Group. Monitoring expenditure and utilization of medicinal products in the European Union countries: a public health approach. *Eur J Public Health*. 2003 Sep;13(3 Suppl): 95-100.

Einarson A, Bonari L, Voyer-Lavigne S, Addis A, Matsui D, Johnson Y, Koren G. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. *Can J Psychiatry*. 2003;48:106-10.

Moretti ME, Caprara D, Coutinho CJ, Bar-Oz B, Berkovitch M, Addis A, Jovanovski E, Schuler-Faccini L, Koren G. Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study. *J Allergy Clin Immunol*. 2003; 111:479-83.

Addis A, Magrini N. New approaches to analysing prescription data and to transfer pharmacoepidemiological and evidence-based reports to prescribers. *Pharmacoepidemiol Drug Saf*. 2002; 11:721-6.

Berkovitch M, Mazzota P, Greenberg R, Elbirt D, Addis A, Schuler-Faccini L, Merlob P, Arnon J, Stahl B, Magee L, Moretti M, Ornoy A. Metoclopramide for nausea and vomiting of pregnancy: a prospective multicenter international study. *Am J Perinatology* 2002;19:311-6.

Buzzetti R, D'Amico R, Addis A. New drug treatment for asthma: clinical versus statistical significance. *Journal of Pediatrics* 2002; 140:484.

Iskedjian M, Einarson TR, MacKeigan LD, Shear N, Addis A, Mittmann N, Ilersich AL. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. *Clinical Therapeutics*. 2002;24:302-16.

Di Gianantonio E, Schaefer C, Mastroiacovo P, Cournot MP, Benedicenti F, Reuvers V, Occupati B, Robert E, Bellemin B, Addis A, Arnon J, Clementi M. Adverse effects of prenatal methimazole exposure. *Teratology* 2001; 64:262-66.

Oh PI, Iskedjian M, Addis A, Lanctot K, Einarson TR. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. *Can J Clinical Pharmacology* 2001;18:199-206.

Einarson A, Fatoye B, Sarkar M, Lavigne S, Brochu J, Chambers C, Mastroiacovo P, Addis A, Matsui D, Schuler L, Einarson TR, Koren G. Pregnancy Outcome Following Gestational Exposure to Venlafaxine: A Multicenter Prospective Controlled Study. *Am J Psychiatry* 2001;158: 1728-1730.

Addis A, Assael Barouk M, Raimo F I farmaci essenziali in pediatria di famiglia Utet Div. Scienze Mediche, Milano, 2001

Addis A, Moretti ME, Fayyazuddin AS, Einarson TR Fetal effects of cocaine: an updated meta-analysis. *Reproductive Toxicology* 2001; 15: 341-69

Addis A, Magrini N, Mastroiacovo P Drug use in pregnancy. *Lancet* 2001; 357:800.

Addis A, Schuler L, Moretti ME, Bonati M, Koren G. Teratogen information services around the world. In: *Maternal-Fetal Toxicology, 3rd Edition*, Koren G.(ed), Dekker, New York 2001.

Addis A, Moretti ME, Syed FA, Einarson TR, Koren G.: Cocaine exposure during pregnancy: A new meta-analysis. In: *Maternal-Fetal Toxicology, 3rd Edition*, Koren G.(ed), Dekker, New York 2001.

Dolovich LR, Addis A, Régis Vaillancourt JM, Barry Power JD, Koren G, and. Einarson TR Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies In: *Maternal-Fetal Toxicology, 3rd Edition*, Koren G.(ed), Dekker, New York 2001.

Bonati M, Addis A.: Pregnancy. In: *Clinical Pharmacology*, Sirtori C, Reidenberg M, Kuhlman, J (eds.) McGraw-Hills International 2000.

Vargas FR, Schuler-Faccini L, Brunoni D, Kim C, Meloni VFA, Sugayama SMM, Albano L, Llerena JC, Almeida JCC, Duarte A, Cavalcanti DP, Goloni-Bertollo E, Conte A, Koren G and Addis A Prenatal exposure to misoprostol and vascular disruption defects: a case control study. *Am J Med Genet* 2000; 95: 302-06.

Opasich C, Russo A, Colombo E, Aldrovandi M, Addis A, Tavazzi L Your cardiac patient wants to become a mother. Risk considerations and advice Part II Your cardiac patient is pregnant. *Ital Heart J* 2000;1: 667-73.

Opasich C, Russo A, Catalano O, Criffo A, De Feo S, Addis A, Tavazzi L Your cardiac patient wants to become a mother. Risk considerations and advice Part I Your cardiac patient ask advice on a possible pregnancy. *Ital Heart J* 2000;1: 605-12.

Addis A, Sharabi S, Bonati M. Risk classification system for drug use during pregnancy. Are they a reliable source of information? *Drug Safety* 2000; 23: 245-53.

Berkovitch M, Elbirt D, Addis A, Schuler-Faccini L, Ornoy A. Fetal effects of metoclopramide therapy for nausea and vomiting of pregnancy. *New England Journal of Medicine* 2000; 343: 445-6.

Einarson A, Mastroiacovo P, Arnon J, Ornoy A, Addis A, Malm H, Koren G. A prospective controlled multicentre study of loperamide in pregnancy. *Canadian Journal of Gastroenterology* 2000;14: 185-87.

Addis A, Dolovich LR, Einarson TR, Koren G. Can one use anxiolytics during pregnancy without anxiety? *Canadian Family Physician Journal* 2000;46: 549-51.

Addis A, Koren G. Safety of fluoxetine during the first trimester of pregnancy: meta-analytical review of epidemiological studies. *Psychological Medicine* 2000;30: 89-94.

Addis A, Bonati M. Use of nimesulide in children. *Lancet* 1999;354:1034.

Addis A, Loebstein R, Koren G, Einarson TR. Meta-analytic review of clinical effectiveness of oral deferiprone (L1). *European Journal of Clinical Pharmacology* 1999; 55: 1-6.

Mastroiacovo P, Mazzone T, Addis A, Elephant E, Carler P, Garbis H, Robert E, Bonati M, Ornory A, Finardi A, Schaffer C, Caramelli L, Rodriguez-Pinilla E, Clementi M. High Vitamin A intake in early pregnancy and congenital malformations: a multicentre prospective controlled study. *Teratology* 1999; 59: 7-11.

Loebstein R, Lalkin A, Addis A, Costa A, Lalkin I, Bonati M, Koren G. Pregnancy outcome following gestational exposure to terfenadine: a multicenter prospective controlled study. *Journal of Allergy and Clinical Immunology* 1999; 104: 953-6.

Bonati M, Addis A. Informing women about drugs they take during pregnancy: promoting consumers' drug information as integral part of care. *Pharmacy world & Science* 1998;20:236-7.

Einarson A, Phillips E, Mawji F, D'Alimonte D, Schick B, Addis A, Mastroiacovo P, Mazzone T, Matsui D, Koren G. A prospective controlled multicentre study of clarithromycin in pregnancy. *American Journal of Perinatology* 1998; 15: 523-5.

Koren G, Nulman I, Addis A. Outcome of children exposed in utero to fluoxetine: a critical review. *Depression Anxiety* 1998; 8 Suppl 1: 27-31.

Lalkin A, Loebstein R, Addis A, Ramezani-Namin F, Mastroiacovo P, Mazzone T, Vial T, Bonati M, Koren G. The safety of omeprazole during pregnancy: a multicenter prospective controlled study. *American Journal Obstetric Gynecology* 1998; 179:727-30.

Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G, Einarson TR. Benzodiazepine in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. *British Medical Journal* 1998; 317: 839-43.

Lalkin A, Loebstein R, Addis A, Koren G. Therapeutic approach to hypertension during pregnancy. *Canadian Family Physician Journal* 1998; 44: 1245-7.

Loebstein R, Addis A, Ho E, Andreou R, Sage S, Donnerfeld AE, Schick B, Bonati M, Moretti M, Lalkin A, Pastuszak A, Koren G. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. *Antimicrobial Agents and Chemotherapy* 1998; 42: 1336-9.

Gruppo collaborativo SPT. Uso di psicofarmaci nelle donne in età fertile che accedono ai servizi psichiatrici territoriali. *Rivista Sperimentale di Freniatria* 1998; 4: 252-60.

Einarson TR, Addis A, Mittmann N, Iskedjian M. Meta-analysis of venlafaxine, SSRIs and TCAs in the treatment of major depressive disorder. *Canadian Journal of Clinical Pharmacology* 1998; 5:205-16.

Iskedjian M, Trakas K, Bradley CA, Addis A, Lactot K, Kruk D, Ilersich AL, Einarson TR. Quality assesment of economic evaluations published in *Pharmacoeconomics*. The first four years (1992-1995). *Pharmacoeconomics* 1997; 12: 685-94.

Lalkin A, Magee L, Addis A, Loebstein R., Koren G.: Acid-suppressing drugs during pregnancy. *Canadian Family Physician Journal* 1997; 43: 1923-4, 1926.

Bailey B, Addis A. Asthma during pregnancy. *Canadian Family Physician Journal* 1997; 43: 1717-8.

Bailey B, Addis A, Lee A, Sanghvi K, Mastroiacovo P, Mazzone T, Bonati M, Paolini C, Garbis H, Val T, De Souza CF, Matsui D, Schechtman AS, Conover B, Lau M, Koren G. Cisapride use during

human pregnancy: a prospective, controlled multicenter study. *Digestive Diseases and Sciences* 1997; 42: 1848-52.

Einarson TR, Addis A, Iskedjian M. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. *Pharmacoeconomics* 1997; 12: 286-96.

Trakas K, Addis A, Kruk D, Buczek Y, Iskedjian M, Einarson TR. Quality assessment of pharmacoeconomic abstracts of original research articles in selected journals. *Annals of Pharmacotherapy* 1997; 31: 423-8.

Addis A, Blowey D, Koren G. Tuberculosis during pregnancy. *Canadian Family Physician Journal* 1996; 42:1461-2.

Oh PI, Einarson TR, Iskedjian M, Addis A, Lanctôt K. Pharmacoeconomic evaluation of risperidone and clozapine in chronic and treatment-resistant schizophrenia. *Ottawa Canadian Coordinating Office for Health Technology Assessment (CCOHTA)* 1996.

Addis A, Impicciatore P, Miglio D, Colombo F, Bonati M, Da Silva CD. Drug use in pregnancy and lactation: the work of a regional drug information centre. *Annals of Pharmacotherapy* 1995; 29:632-3.

Bonati M, Nannini S, Addis A. Vitamin A supplementation during pregnancy in developed countries. *Lancet* 1995; 345:736-7.

Addis A, Miglio D., Da Silva C.D.C., Colombo Fabio, Bonati M.: Drug use in pregnancy from the viewpoint of a regional drug information centre. In: *Health information centres in Europe. What is their status? How should they develop?* Bonati M., Tognoni G. (eds); IRFMN, Milano 1995; 23-26

Fortoni G, Angeretti N, Amoroso D, Addis A, Consolo S. Decrease in [3H] hemicholinium binding to high-affinity choline uptake sites in deafferented striatum: restoration by oxiracetam. *Brain Research* 1990; 530:156-60.